Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma
Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma
复制标题
滤泡性淋巴瘤中 Bcl-2/IgH 重排的发生率和临床意义
DOI：
10.1080/1042819021000050052
复制
发表时间：
2003
影响因子：
2.6
通讯作者：
E. Montserrat
中科院分区：
文献类型：
--
作者：
S. Montoto;A. López;D. Colomer;J. Esteve;F. Bosch;A. Ferrer;N. Villamor;C. Moreno;E. Campo;E. Montserrat
Bcl-2 / IgH重排是滤泡性淋巴瘤（FL）的分子标志，其在诊断时存在于70-90%的病例中。这个特征的临床意义是有争议的。本研究的目的是通过PCR技术分析bcl-2 / IgH重排，并将分子结果与临床特征和结果相关联。该研究纳入了同一机构中诊断为FL的69名患者（中位年龄53岁;男性/女性比例：35/34）。共分析了77份DNA样本，其中54份来自淋巴结活检，23份来自外周血或骨髓。通过PCR技术评估Bcl-2 / IgH重排的主要断点区域（MBR）和次要簇区域（mcr）断点。60例可评估样本中的39例（65%）在MBR断点发现bcl-2 / IgH重排，而在1例患者（2%）中观察到mcr中的bcl-2 /IgH重排，其余20例患者（33%）在MBR或mcr中未观察到重排。关于初始特征，在MBR或mcr时有bcl-2 / IgH重排的患者比在这些位点没有重排的患者年轻（<65岁）（p =0.0001）。根据bcl-2 / IgH重排，在完全缓解率、治疗失败时间和总生存率方面没有发现差异。在我们的研究中，67%的患者在MBR或mcr时发现bcl-2 / IgH重排，这与治疗反应、生存率和治疗失败时间无关。
Bcl-2 / IgH rearrangement is the molecular hallmark of follicular lymphoma (FL) which is present in 70-90% of the cases at diagnosis. The clinical significance of this feature is controversial. The aim of this study was to analyze the bcl-2 / IgH rearrangement by means of a PCR technique, and to correlate molecular findings with clinical characteristics and outcome. Sixty-nine patients (median age, 53 years; male/female ratio: 35/34) diagnosed with FL in a single institution were included in the study. A total of 77 DNA samples were analyzed, 54 were obtained from lymph node biopsy and 23 from peripheral blood or bone marrow. Bcl-2 / IgH rearrangement was assessed for both the major breakpoint region (MBR ) and the minor cluster region (mcr ) breakpoints by a PCR technique. Thirty-nine out of sixty patients (65%) with assessable samples were found to have a bcl-2 / IgH rearrangement in the MBR breakpoint, whereas bcl-2 / IgH rearrangement in mcr was observed in one patient (2%) and no rearrangement at MBR or mcr in the remaining 20 patients (33%). Regarding the initial characteristics, patients with bcl-2 / IgH rearrangements at MBR or mcr were younger (<65 years) than those with no rearrangement at these sites (p =0.0001). No differences were found according to bcl-2 / IgH rearrangement in terms of complete response rate, time to treatment failure and overall survival. In our series bcl-2 / IgH rearrangement at MBR or mcr, which was found in 67% of the patients, was not correlated with response to treatment, survival nor time-to-treatment-failure.
登录
查看更多内容
影响因子：
158.5
作者：
WEISS, LM;WARNKE, RA;CLEARY, ML
通讯作者：
CLEARY, ML
通过聚合酶链式反应和对滤泡性淋巴瘤中酶促扩增 DNA 的直接基因组测序来检测 bcl-2 小簇区域内的染色体易位 t(14;18)。
影响因子：
20.3
作者：
Ngan,BY;Nourse,J;Cleary,ML
通讯作者：
Cleary,ML
Bcl-2 蛋白表达和 Bcl-2 基因重排在弥漫性侵袭性非霍奇金淋巴瘤中的预后意义。
影响因子：
20.3
作者：
Gascoyne,RD;Adomat,SA;Krajewski,S;Krajewska,M;Horsman,DE;Tolcher,AW;O'Reilly,SE;Hoskins,P;Coldman,AJ;Reed,JC;Connors,JM
通讯作者：
Connors,JM
所有具有聚合酶链式反应可放大 bcl-2 断点的晚期非霍奇金淋巴瘤在评估时和治疗后均具有含有 bcl-2 重排的残留细胞。
影响因子：
20.3
作者：
Gribben,JG;Freedman,As;Woo,SD;Blake,K;Shu,RS;Freeman,G;Longtine,JA;Pinkus,GS;Nadler,LM
通讯作者：
Nadler,LM